CY1107725T1 - Ενας ογκολυτικος αδενοϊος - Google Patents

Ενας ογκολυτικος αδενοϊος

Info

Publication number
CY1107725T1
CY1107725T1 CY20071101140T CY071101140T CY1107725T1 CY 1107725 T1 CY1107725 T1 CY 1107725T1 CY 20071101140 T CY20071101140 T CY 20071101140T CY 071101140 T CY071101140 T CY 071101140T CY 1107725 T1 CY1107725 T1 CY 1107725T1
Authority
CY
Cyprus
Prior art keywords
calculative
gland
vectors
adenovirus
responsive
Prior art date
Application number
CY20071101140T
Other languages
English (en)
Inventor
Leisa Johnson
Ali Fattaey
Terry Hermiston
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CY1107725T1 publication Critical patent/CY1107725T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Περιγράφονται φορείς ιών και μέθοδοι παρασκευής τέτοιων φορέων οι οποίοι κατά προτίμηση σκοτώνουν νεοπλαστικά αλλά όχι κανονικά κύτταρα, ο προτιμώμενος φορέας είναι ένας αδενοϊός που έχει τους ενδογενείς υποκινητές στις Ε1Α και/ή Ε4 περιοχές υποκατεστημένους με έναν υποκινητή ειδικό για όγκους ο οποίος είναι κατά προτίμηση E2F αποκρινόμενος.
CY20071101140T 1999-11-15 2007-09-03 Ενας ογκολυτικος αδενοϊος CY1107725T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16563899P 1999-11-15 1999-11-15
EP00978753A EP1230378B1 (en) 1999-11-15 2000-11-14 An oncolytic adenovirus

Publications (1)

Publication Number Publication Date
CY1107725T1 true CY1107725T1 (el) 2013-04-18

Family

ID=22599791

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101140T CY1107725T1 (el) 1999-11-15 2007-09-03 Ενας ογκολυτικος αδενοϊος

Country Status (13)

Country Link
US (1) US7001596B1 (el)
EP (1) EP1230378B1 (el)
JP (1) JP4334174B2 (el)
CN (1) CN1382218A (el)
AT (1) ATE364091T1 (el)
AU (1) AU776061B2 (el)
CA (1) CA2380537C (el)
CY (1) CY1107725T1 (el)
DE (1) DE60035124T2 (el)
DK (1) DK1230378T3 (el)
ES (1) ES2288488T3 (el)
PT (1) PT1230378E (el)
WO (1) WO2001036650A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037274A1 (en) * 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
US7078030B2 (en) * 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
WO2004042025A2 (en) 2002-11-01 2004-05-21 Cell Genesys, Inc. Cell-specific adenovirus vector comprising ebv-specific promoter
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20040191761A1 (en) * 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
US20050095705A1 (en) * 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
CN1528887A (zh) * 2003-10-15 2004-09-15 中国科学院上海生命科学研究院 肿瘤靶向双基因-病毒的构建方法
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US7714119B2 (en) * 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
US7943373B2 (en) * 2004-09-29 2011-05-17 Oncolys Biopharma, Inc. Telomelysin/GFP-expressing recombinant virus
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
US7621843B2 (en) * 2007-01-17 2009-11-24 General Electric Company Apparatus for restraining axial movement of a ring gear in a gearbox for a wind turbine
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
CN101928696B (zh) * 2008-09-27 2012-08-15 中国人民解放军军事医学科学院放射与辐射医学研究所 一种前列腺癌靶向腺病毒的制备及应用
ES2536747T3 (es) 2009-01-20 2015-05-28 Transgene Sa ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
RU2555340C2 (ru) 2009-04-17 2015-07-10 Трансжене Са Биомаркер для мониторинга пациентов
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
JP5650212B2 (ja) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者を選択するためのバイオマーカーおよび関連方法
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
US9017672B2 (en) 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CN103463646A (zh) * 2013-09-19 2013-12-25 浙江大学 E2f1蛋白在制备诊断和治疗骨肉瘤药物中的应用
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
AU682854B2 (en) * 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0707071B1 (en) * 1994-08-16 2003-07-30 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6197293B1 (en) * 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
WO1998013508A1 (en) 1996-09-24 1998-04-02 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
US6432700B1 (en) * 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
GB9906815D0 (en) * 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents

Also Published As

Publication number Publication date
WO2001036650A2 (en) 2001-05-25
WO2001036650A3 (en) 2001-11-22
CA2380537A1 (en) 2001-05-25
EP1230378A2 (en) 2002-08-14
ATE364091T1 (de) 2007-06-15
DE60035124T2 (de) 2008-02-07
ES2288488T3 (es) 2008-01-16
AU1618101A (en) 2001-05-30
US7001596B1 (en) 2006-02-21
CN1382218A (zh) 2002-11-27
DE60035124D1 (en) 2007-07-19
PT1230378E (pt) 2007-09-17
EP1230378B1 (en) 2007-06-06
JP4334174B2 (ja) 2009-09-30
JP2003535575A (ja) 2003-12-02
AU776061B2 (en) 2004-08-26
CA2380537C (en) 2011-01-18
DK1230378T3 (da) 2007-10-08

Similar Documents

Publication Publication Date Title
CY1107725T1 (el) Ενας ογκολυτικος αδενοϊος
ATE320271T1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
WO2005060515A3 (en) An oncolytic adenovirus
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE69734930D1 (de) Adenovirales fiberprotein mit einem kurzen schaft und seine verwendung
DK0981607T3 (da) Modificeret arginin-deiminase
NZ336829A (en) Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
EP1053013A4 (en) ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
NO961696L (no) Rekombinant p53 adenovirus, fremgangsmåter og blandinger
DK1226264T3 (da) Cellelinjer og konstruktioner, der er nyttige i fremstillingen af E1-deleterede adenovirus i fravær af replikationskompetent adenovirus
WO1998039466A3 (en) Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
EP0710288A4 (en) ADENOVIRAL VECTORS FOR TREATMENT OF HEMOPHILIA
IS4762A (is) Samfallandi eitlaveiru genaferjukerfi og frumulínur
FI900554A0 (fi) Expressionssystem foer amidation av enzym.
EP0948522A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS CAPABLE OF MODULATING CELLULAR RECEPTIVITY TO CYTOKINES
EP0163304A3 (en) Human monoclonal antibodies to intermediate filaments
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
WO1999036545A3 (en) Adenoviral vectors with modified capsid proteins
TR199901695T2 (xx) Havu� antifriz polipeptidleri.
DK0783585T3 (da) Defekte rekombinante adenovira med et inaktiveret IVa2-gen
WO2001092547A3 (en) Modified bovine adenovirus having altered tropism
PL376573A1 (pl) Nowe adenowirusy, kodujące je kwasy nukleinowe i ich zastosowanie
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DE60039032D1 (de) Regulatorische konstrukte, die das intron 3 des pr